PMA device
Apligraf
Organogenesis, Inc. · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision May 3, 2000, newest Jun 25, 2013BurnsChronic wounds and ulcers
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
11
Naming "Apligraf"
MAUDE reports
6
Brand "Apligraf", since 2015
PubMed studies
123
Mentioning "Apligraf"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Apligraf
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- APLIGRAFPMA supplement
P950032-S073 · Decided Jun 25, 2013 · 35 days after receipt · Normal 180 Day Track No User Fee
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
- APLIGRAFPMA supplement
P950032-S034 · Decided Oct 15, 2002 · 71 days after receipt · Normal 180 Day Track
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
- APLIGRAF(GRAFTSKIN)PMA supplement
P950032-S022 · Decided Apr 26, 2001 · 99 days after receipt · Normal 180 Day Track
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Apligraf", any status and sponsor, newest update first.
Acera Surgical, Inc.Not on our public-company list
NCT04927702 · 48 participants · Start Jul 19, 2021 · Primary completion Jul 15, 2024
Device: Synthetic Hybrid-Scale Fiber Matrix; Standard of Care and 1 more · For: Diabetic Foot Ulcer; Venous Leg Ulcer
Sites: Vista, California; Jacksonville, Florida; Miami Beach, Florida · 6 sites in all
- AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot UlcersPivotal-lookingCompleted
Integra LifeSciences CorporationPublic (IART)
NCT03547635 · 116 participants · Start May 3, 2018 · Primary completion Feb 26, 2019
Device: A Marketed Comparator · For: Diabetic Foot Ulcer
Sites: Fresno, California; Los Angeles, California; Gainesville, Georgia · 7 sites in all
- The Diabetic Foot Ulcer RegistryStatus unknown
U.S. Wound RegistryAcademic, hospital or other
NCT02813161 · 10,000 participants (planned) · Start Feb 2015 · Primary completion Jan 2025
Device: negative pressure wound therapy; off-loading and 1 more · For: Diabetic Foot Ulcer Outcome; Quality of Patient Care
Sites: The Woodlands, Texas
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Apligraf", and for the whole product code for context.
This brand
6 reports: 0 malfunction, 6 injury, 0 death
Whole product code MGR
11 reports: 1 malfunction, 9 injury, 0 death
Newest reports for this brand
- APLIGRAFInjury
MW5167981 · Received Mar 21, 2025 · Event dated Dec 27, 2024
Device type: Cultured Human Cell Skin Dressing (PFC)
Patient problem as coded: Erythema; Granuloma; Local Reaction; Impaired Healing; Swelling/ Edema
- APLIGRAFInjury
1221816-2019-00001 · Received Mar 21, 2019 · Event dated Feb 28, 2019
Device type: Cultured Human Cell Skin Dressing (PFC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cellulitis
- APLIGRAFInjury
1221816-2018-00002 · Received Jun 7, 2018 · Event dated May 20, 2018
Device type: Cultured Human Cell Skin Dressing (PFC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1747-2011 · Started Feb 21, 2011 · Posted by FDA Mar 23, 2011
Reason given: Product sterility may be compromised
Cause as FDA categorized it: Packaging process control · Device type: Dressing, Wound And Burn, Interactive (MGR)
Z-1746-2011 · Started Jan 30, 2011 · Posted by FDA Mar 23, 2011
Reason given: Product sterility compromised
Cause as FDA categorized it: Material/Component Contamination · Device type: Dressing, Wound And Burn, Interactive (MGR)
Z-2589-2010 · Started Aug 2, 2010 · Posted by FDA Sep 28, 2010
Reason given: Product is contaminated with a yeast identified as Pseudozyma antarctica.
Cause as FDA categorized it: Process control · Device type: Dressing, Wound And Burn, Interactive (MGR)
3 more recall records with a free account
Published research
The most relevant PubMed records for "Apligraf"[tiab]. The summary above synthesizes these.
- Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.
Hu S, Kirsner RS, Falanga V, et al. · Wound Repair Regen · 2006Comparative Study, Multicenter Study
- Apligraf in the treatment of neuropathic diabetic foot ulcers.
Edmonds M · Int J Low Extrem Wounds · 2009Multicenter Study, Randomized Controlled Trial
- The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
Redekop WK, McDonnell J, Verboom P, et al. · Pharmacoeconomics · 2003Comparative Study, Research Support, Non-U.S. Gov't
- Survival of Apligraf in acute human wounds.
Griffiths M, Ojeh N, Livingstone R, et al. · Tissue Eng · 2004Clinical Trial, Controlled Clinical Trial
- Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers.
Fivenson D, Scherschun L · Int J Dermatol · 2003Evaluation Study, Research Support, Non-U.S. Gov't
- The use of Apligraf in acute wounds.
Kirsner RS · J Dermatol · 1998Review
- Innovative therapies in wound healing.
Shen JT, Falanga V · J Cutan Med Surg · 2003Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
Trent JF, Kirsner RS · Int J Clin Pract · 1998Review
- Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa.
Fivenson DP, Scherschun L, Cohen LV · Plast Reconstr Surg · 2003Research Support, Non-U.S. Gov't
- Apligraf as an Alternative to Skin Grafting in the Pediatric Population.
Eudy M, Eudy CL, Roy S · Cureus · 2021Case Reports
- Apligraf treatment of venous ulcers and other chronic wounds.
Falanga V · J Dermatol · 1998Review
- Update on tissue-engineered biological dressings.
Ehrenreich M, Ruszczak Z · Tissue Eng · 2006Review
Other devices of this type
Also filed under product code MGR.
- TranscyteShire Regenerative Medicine · PMA 2004
- DermagraftShire Regenerative Medicine · PMA 2012
- Integra Dermal Regeneration TemplateIntegra Lifesciences Corp. · PMA 2017
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Apilgraf(Graftskin)Organogenesis, Inc. · PMA 2002
- Orcel Bilayered Cellular MatrixForticell Bioscience · PMA 2001
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.